| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Biotechnology
The Quantellect read. RZLT rose 5.85% in the Nov 18 session to $4.25. The borrow fee is 0.49%. Nine active firms cover the stock as of Nov 19, 2026; eight active firms with targets average $10.13 over 12 months. Descriptive summary of the data on this page, not a recommendation.
—
RSI (14) 50.1 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price $4.25 · As of Nov 18, 2026, 3:59 PM ET
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
RZLT · NASDAQ · USD
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
— · Industry comparison not available
Buy
Based on 9 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 8 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →— · Smart-money activity not available
All smart-money activity →GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.